<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211275</url>
  </required_header>
  <id_info>
    <org_study_id>NL25655.031.08</org_study_id>
    <nct_id>NCT01211275</nct_id>
  </id_info>
  <brief_title>Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma</brief_title>
  <acronym>N08CPA</acronym>
  <official_title>A Randomized Phase I/II Study of Standard Chemotherapy (Cisplatin and Pemetrexed) With or Without Axitinib in Patients With Malignant Mesothelioma: Interim Biopsy Analysis to Determine Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of axitinib, a potent angiogenesis
      inhibitor, on tissue and clinical outcome in combination with chemotherapy given to patients
      with mesothelioma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the effects of the addition of axitinib to standard chemotherapy on tissue
      samples with respect to micro-vessel density (MVD): expression of VEGF-Receptor; PDGF
      receptor expression; extent of necrosis and apoptosis.

      To determine the safety of the addition of axitinib (to a maximum of the recommended dose of
      maximally 2 x 10 mg per day) to the standard treatment with cisplatin and pemetrexed.

      To determine the feasibility of performing a (second) thoracoscopy after 10 weeks of the
      combination treatment with cisplatin, pemetrexed and axitinib.

      Serum samples will be collected and tested for inhibiting effects in a tube formation and
      spheroid sprouting assay.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 22, 2009</start_date>
  <completion_date type="Actual">May 6, 2013</completion_date>
  <primary_completion_date type="Actual">November 13, 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To test the impact of the addition of axitinib to standaard chemotherapy treatment on histology samples</measure>
    <time_frame>micro-vessel density;expression of VEGF and PDGF receptor; extent of necrosis and apoptosis</time_frame>
    <description>To determine the effects of the addition of axitinib to standard chemotherapy on tissue samples with respect to micro-vessel density (MVD); expression of VEGF-Receptor; PDGF receptor expression; extent of necrosis and apoptosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the side effects of the standard chemotherapy and the additional risks related to axitinib use</measure>
    <time_frame>AE;SAE;SUSAR</time_frame>
    <description>hypertension, fatigue, abdominal discomfort</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>axitinib + cisplatin + premetrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cisplatin + premetrexed</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>axitinib</intervention_name>
    <description>axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.</description>
    <arm_group_label>arm 2</arm_group_label>
    <other_name>cisplatin</other_name>
    <other_name>alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.</description>
    <arm_group_label>arm 1</arm_group_label>
    <other_name>cisplatin</other_name>
    <other_name>alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or cytologically diagnosed malignant mesothelioma

          -  age &gt; 18 years

          -  Medically suitable for limited surgical intervention (pleural biopsies or limited
             pleurectomy)

          -  Measurable or evaluable disease is not required

          -  Ability to understand the study and give signed informed consent including the
             approval to accept a second thoracoscopic or surgical treatment after the third course

          -  No previous chemotherapy

          -  Radiotherapy is allowed when this is given for palliation, the interval is &gt; 4 weeks,
             not more than 1/3 of the bone marrow capacity or all tumor is within the irradiation
             field.

          -  WHO performance status =&lt; 2

          -  Adequate organ function as evidenced by the following peripheral blood counts or serum
             chemistries at study entry:

        Hematology:

          -  ANC=&gt;1.5 x 109/L,

          -  Platelets=&gt;150 x 109/L,

          -  Hemoglobin =&gt; 6,0 mmol/l

        Chemistry:

          -  total serum bilirubin &lt; UNL;

          -  AST and ALT= &lt; 2.5xUNL,

          -  AP &lt; 5xUNL (unless bone metastases are present in the absence or any liver disease)

          -  Serum creatinine =&lt; 2xUNL

        Exclusion Criteria:

          -  Active uncontrolled infection, severe cardiac dysfunction or uncorrectable bleeding
             tendency

          -  Previous successful pleurodesis

          -  Uncontrolled hypertension

          -  Symptomatic peripheral neuropathy =&gt; grade 2 according to NCIC CTC,version 3.0

          -  Presence of symptomatic CNS metastases

          -  Unstable peptic ulcer, unstable diabetes mellitus or other serious disabling condition

          -  Concomitant administration to any other experimental drugs under investigation

          -  Impaired renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P Baas, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoekziekenhuis (NKI-AVL)</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesothelioma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>translational research</keyword>
  <keyword>axitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

